Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE versus PAMINE FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE versus PAMINE FORTE.
ATROPINE vs PAMINE FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine and other cholinergic agonists. Inhibits vagal activity, increases heart rate, reduces secretions, and relaxes smooth muscle.
Anticholinergic agent; competitively blocks acetylcholine at muscarinic receptors, reducing gastrointestinal motility and secretory activity.
0.5-1 mg IV/IM/SC every 3-5 minutes as needed, up to a total of 3 mg (adults). For preoperative use, 0.4-0.6 mg IM/IV 30-60 minutes before anesthesia.
1 tablet (5 mg) orally 4 times daily, before meals and at bedtime.
None Documented
None Documented
2-4 hours (terminal); prolonged in elderly and neonates; clinically requires dosing every 4-6 hours
Clinical Note
moderateBenzatropine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Dronedarone
1.5-2 hours; prolonged in renal impairment
Renal (30-50% unchanged; remainder as inactive metabolites via hydrolysis and glucuronidation); 50-70% of a dose renally excreted as metabolites; <5% fecal
Renal (70% unchanged), biliary/fecal (30%)
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent
"The metabolism of Dronedarone can be decreased when combined with Benzatropine."